In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Cardiometabolic risk factors in hypertensive children and adolescents: The PEP Family Heart Study

Session Best Posters 5

Speaker Peter Schwandt

Congress : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention - Epidemiology
  • Session type : Best Posters
  • FP Number : P4387

Authors : P Schwandt (Munich,DE), T Bertsch (Nuremberg,DE), GM Haas (Munich,DE)


P. Schwandt1 , T. Bertsch2 , G.M. Haas1 , 1Arteriosclerosis Prevention Institute - Munich - Germany , 2Institute of Clinical Chemistry,Laboratory and Transfusion Medicine, Central Laboratory - Nuremberg - Germany ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 878

Background: Pediatric hypertension is more likely to develop in overweight and obese subjects.

Purpose: To assess the prevalence of overweight and other anthropometric and laboratory cardiovascular disease (CVD) risk factors among 3–18 years old subjects participating in the PEP Family Heart Study Nuremberg

Methods: Using LMS 2.1 and SPSS 21 we calculated in 7,076 children and adolescents the age-, gender- and height-adjusted percentiles (and cut-offs) for eight risk variables: overweight (85–95thpctl) abdominal adiposity (waist circumference ≥90thpctl), Non HDL-C (≥95thpctl), Triglycerides (TG≥95thpctl), High Density Cholesterol (HDL-C <5thpctl), TG/HDL-C-Ratio (>90th), LDL- C (≥95thpctl), and fasting plasma glucose (FPG) >95thpctl. Hypertension was defined as SBP and/or DBP ≥95thpctl.

Results: In 361 hypertensive males/females the prevalence was higher than in 6,707 normotensive males/females for overweight (12.8/22.4% vs. 9 9/8.6%), obesity (17.3/24.2% vs. 4.8/3.6%) and abdominal adiposity (22.4/33.9% vs. 10.0/9.2). The effect of relative adiposity on BP was minimal until the beginning of the overweight category at the 85th percentile of BMI, at which point BP steeply increased in both genders. The prevalence of abnormal laboratory risk variables was not much different between hypertensive and normotensive males/females for increased FPG (7.7/10.3% vs. 9.1/6.8%), Non HDL-C 21.4/26.1% vs. 20.6/21.8%, TG 1.5/6.1% vs. TG 1.4/2.2%, low HDL-C 2.1/3.6% vs. 2.1/2.6% except the TG/HDL-C ratio 17.9/1.8% vs. 11.2/14.3. The significant age- and gender adjusted associations between children and adolescents with and without hypertension were OR 1.5 (95% CI 1.2–2,0) for the increased TG/HDL-C ratio ≥2.27 suggesting insulin resistance, for overweight OR 2.1 (95% CI 1.6–2.8) and for abdominal adiposity OR 3.6 (95% CI 2.8–4.6). Whereas 91.4% of normotensive males and 91.1% of normotensive females had less than one risk factor 86.1% of the hypertensive males and 76.1% of the hypertensive females had less than one additional risk factor.

Conclusions: Hypertensive children and adolescents who participated in the PEP Family Heart Study Nuremberg had a 2.1 times higher risk for overweight, a 3.6 fold higher risk for abdominal adiposity and were at a 1.5 times higher risk of being insulin resistant,

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are